Equity Overview
Price & Market Data
Price: $3.26
Daily Change: -$0.14 / 4.29%
Daily Range: $3.22 - $3.40
Market Cap: $4,310,893
Daily Volume: 4,563
Performance Metrics
1 Week: -0.91%
1 Month: -4.12%
3 Months: 20.70%
6 Months: -36.08%
1 Year: -73.92%
YTD: -29.89%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.